You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY22 is not expected to be complete until September, 2023.

Download all SBIR.gov award data either with award abstracts (290MB) or without award abstracts (65MB). A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.

  1. Pre-clinical Development of a Vaccine for the Treatment of Heroin Addiction

    SBC: Molecular Express Inc            Topic: R42

    DESCRIPTION provided by applicant Heroin and related opioids are highly addictive drugs known for their analgesic properties Since the number of heroin users in the United States has skyrocketed reaching epidemic levels Abuse of prescription opioid pain relievers oxycodone Oxycotin and hydrocodone Vicodin which are known gateway drugs to heroin has also increased dramatically Beca ...

    STTR Phase II 2015 Department of Health and Human ServicesNational Institutes of Health
  2. BlueBox- a complete code blue data recorder

    SBC: NeoVative, Inc.            Topic: 400

    DESCRIPTION provided by applicant andquot Code blue andquot the term used in hospitals to call for an immediate cardiopulmonary resuscitation CPR signals dire emergencies where medical errors can occur and lives can be lost Reviewing CPR performance of the code blue team is a cornerstone for improving outcomes Thorough and accurate recording of code blue events enable detailed reviews to ...

    STTR Phase I 2015 Department of Health and Human ServicesNational Institutes of Health
  3. Developing efficient and safe cell-permeable reprogramming peptides for generation of iPS cells.

    SBC: Vivoscript, Inc.            Topic: 200

    DESCRIPTION provided by applicant The groundbreaking discovery of induced pluripotent stem cells iPSCs has opened a new page for developing personalized cell based therapies against various devastating human diseases without ethical concerns of using human embryonic stem cells However the future clinical applications of iPSCs remain in doubt due to potential risks of undesired genomic alter ...

    STTR Phase I 2015 Department of Health and Human ServicesNational Institutes of Health
  4. Electronic Optimization of Stem Cell Derived Human Cardiac Myocytes

    SBC: Cytocybernetics Inc            Topic: NHLBI

    DESCRIPTION provided by applicant As part of the FDA approval process for novel therapeutic drugs safety screening demonstrating that the new drug does not have deleterious effects on the human cardiac action potential is required Healthy human heart cells are not available for such preclinical drug testing There is currently no consensus on the best experimental approach to provide the most ...

    STTR Phase I 2015 Department of Health and Human ServicesNational Institutes of Health
  5. Asthmagram: objective assessment of asthma symptoms in children

    SBC: NeoVative, Inc.            Topic: NHLBI

    DESCRIPTION provided by applicant Asthma is the most common chronic illness of childhood but many children have poorly controlled symptoms causing morbidities hospitalizations and costs The first step toward good asthma control is accurate assessment of symptoms Recall of the frequency and severity of symptoms is the cornerstone of asthma assessment Unfortunately recall by parents or ...

    STTR Phase I 2015 Department of Health and Human ServicesNational Institutes of Health
  6. Evaluation of TRB-N0224, a Proprietary Chemically Modified Curcumin, for the Treatment of Periodontal Disease in a LPS-Induced Rat Model

    SBC: TRAVERSE BIOSCIENCES, INC.            Topic: NIDCR

    DESCRIPTION provided by applicant Traverse Biosciences Inc is a pre clinical stage drug development company working to commercialize new chemical entities which act to resolve inflammatory conditions through pleiotropic host modulation of pathologically unrestrained matrix metalloproteinases MMPs and pro inflammatory cytokines The companyandapos s lead drug candidate TRB N is a propri ...

    STTR Phase I 2015 Department of Health and Human ServicesNational Institutes of Health
  7. A Visual Assessment System for Retinal Function/Drug Discovery

    SBC: AFASCI, INC.            Topic: N

    DESCRIPTION provided by applicant Preclinical evaluation of treatment strategies for retinal neurodegenerative diseases is highly dependent on mouse models Classical methods to assess the visual function of animals such as electroretinogram ERG which measures electrical responses in the retina do not address connections between the eye and brain or visual perception by the visual system ...

    STTR Phase I 2015 Department of Health and Human ServicesNational Institutes of Health
  8. Mass Spectrometric Screening of the Effect of Chemical Toxicants on the Human Epitranscriptome during Stem Cell Differentiation

    SBC: ATHGHIN BIOTECHNOLOGY, INC.            Topic: 113

    DESCRIPTION provided by applicant Epitranscriptomics explores levels and evolution of RNA modifications as a response from intra and inter cellular stimuli These modifications and the levels at which they are present are emerging as important regulators of biological processes Perturbations such as chemical toxicants exposure can alter the patterns of specific modifications on RNA sub types ...

    STTR Phase I 2015 Department of Health and Human ServicesNational Institutes of Health
  9. The Development of a High-Throughput Assay to Screen Chemical Compounds in Human Pluripotent Stem Cell Derived Neural Cells

    SBC: ATHGHIN BIOTECHNOLOGY, INC.            Topic: 113

    DESCRIPTION provided by applicant The long term objective of this application is to provide a high throughput platform to test the effects of chemical exposure on human brain development In the US chemicals are not required for health or environmental safety testing before their incorporation in consumer products Over registered chemicals are in commerce most of which are used withou ...

    STTR Phase I 2015 Department of Health and Human ServicesNational Institutes of Health
  10. Clinical Translation of an Anti-Metastatic Antibody for Breast Cancer Therapy

    SBC: FOR-ROBIN, INC.            Topic: 102

    DESCRIPTION provided by applicant Translational studies are proposed to support the continued development of the JAA F antibody based therapy to address the critical need for a safe and effective treatment for metastatic breast cancer including triple negative breast cancers Building on the success of our Phase I project the overarching objectives of the Phase II application are to advanc ...

    STTR Phase II 2015 Department of Health and Human ServicesNational Institutes of Health
US Flag An Official Website of the United States Government